Document is current
Any future updates will be listed below
-
Authors
Charoenngam, Nipith https://orcid.org/0000-0002-6501-6180
Ponvilawan, Ben
Thongpiya, Jerapas
Yingchoncharoen, Pitchaporn
Chaikijurajai, Thanat
Chaisidhivej, Natapat
Apovian, Caroline M.
Ungprasert, Patompong
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK046200)
- License Information
-
More Information
Article History
Received: 10 September 2021
Accepted: 21 December 2021
First Online: 5 January 2022
Declarations
:
: Caroline M. Apovian reports receiving personal fees from Nutrisystem, Zafgen, Sanofi-Aventis, Orexigen, EnteroMedics, GI Dynamics, Scientific Intake, Gelesis, Novo Nordisk, SetPoint Health, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, and Takeda outside of the funded work; reports receiving grant funding from Aspire Bariatrics, GI Dynamics, Orexigen, Takeda, the Vela Foundation, Gelesis, Energesis, Coherence Lab, and Novo Nordisk outside of the funded work; and reports past equity interest in ScienceSmart, LLC. S.A. receives research grant funding from Novo Nordisk. The rest of the authors declare no conflicts of interest.
